Home
|
News
|
Events
|
Contact Us
|
English
|
繁體中文
|
日本語
About Us
Product & Service
Facilities
Quality & Compliance
For Investors
Career
|
Company
|
Milestone
|
People
|
Mission Statement
|
Organization
|
Contact Us
|
|
Active Pharmaceutical Ingredients
|
Contract Development and Manufacturing Organization (CDMO)
|
Antibody Drug Conjugates (ADCs)
|
Injectable Manufacturing Services
|
|
Kilo Lab
|
Commercial Production
|
High Potency API (HPAPI)
|
Analytical instrument
|
|
DMFs & CEPs
|
Inspection
|
Certificates
|
SHE Policy
|
Intellectual Property
|
Award
|
|
Financials
|
Corporate Governance
|
Shareholder Services
|
CSR
|
FAQ
About Us
Home
/
About Us
/
News
/
Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-301 for the Treatment of Inflammation and Pain after Cataract Surgery
Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-301 for the Treatment of Inflammation and Pain after Cataract Surgery
more
next»
2022-05-13
Please click here for details:
https://www.formosapharma.com/2022/05/12/formosa-pharmaceuticals-and-aimmax-therapeutics-announce-successful-top-line-results-from-cpn-301-for-the-treatment-of-inflammation-and-pain-after-cataract-surgery/
Copyright ©2014 Formosa Laboratories, Inc. All Rights Reserved.
丙肝
